Postcards: race and medicine in the 21st century

[摘要] On 20 July 2004, it was reported that BiDil®, a drug aimed specifically at African Americans to treat heart failure, has proven so successful in a clinical trial conducted in the US that it was ended early.1 The pharmaceutical company sponsoring the development of BiDil and the clinical trial to assess its efficacy, NitroMed Pharmaceuticals, hope that this will now lead the US Food and Drug Administration (FDA) to approve BiDil for prescription. BiDil could be the first of several ‘ethnically-tailored’ drugs to appear in the near future, with implications for the way drugs are prescribed by GPs and other clinicians.

[学科分类] 卫生学